FDA
-
-
-
-
-
-
-
Insmed (INSM) PT Raised to $213 at BofA Securities
-
-
-
-
-
-
-
Chronic Rare Diseases in an Aging America: Why HyBryte and Federal Policy Matter Now
-
-
-
-
-
-
-
RBC Capital on Biotech: 'Who Wins and Who Loses If RFK, Jr. Goes'
-
-
-
-
-
-
-
FDA Approves BRINSUPRI⢠(brensocatib) as the First and Only Treatment for Non-Cystic Fibrosis Bronchiectasis, a Serious, Chronic Lung Disease
-
-
-
-
-
-
-
Truist on Insmed (INSM): 'TPIP Data Is a Clearing Event'
-
-
-
-
-
-
-
Biotech sector Q1 earnings preview from RBC Capital Markets
-
-
-
-
-
-
-
FDA Grants Priority Review to Insmed's Brensocatib for Treatment of Bronchiectasis with PDUFA Target Action Date Set for August 12, 2025
-
323,885 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

